DIADEXUS INC COM USD0.01 (DDXS)

0.03
0.00 (0.00)
OTC
Prev Close 0.03
Open 0.03
Day Low/High 0.03 / 0.03
52 Wk Low/High 0.01 / 4.50
Volume 1.64K
Exchange OTC
Shares Outstanding 4.10B
Market Cap 82.00K
Div & Yield N.A. (N.A)

Latest News

DiaDexus, Inc. Reports Third Quarter 2014 Financial Results

DiaDexus, Inc. Reports Third Quarter 2014 Financial Results

diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the third quarter ended September 30, 2014.

DiaDexus, Inc. To Report Third Quarter 2014 Financial Results On November 5, 2014

DiaDexus, Inc. To Report Third Quarter 2014 Financial Results On November 5, 2014

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it will report third quarter 2014 financial results on Wednesday, November 5,...

DiaDexus, Inc. Announces Appointment Of Kenneth Fang, M.D., As Chief Medical Officer

DiaDexus, Inc. Announces Appointment Of Kenneth Fang, M.D., As Chief Medical Officer

diaDexus, Inc. (OTCQB:DDXS), a commercial stage developer of proprietary cardiovascular diagnostic products, today announced that Kenneth C.

DiaDexus, Inc. Announces Resignation Of Chief Financial Officer

DiaDexus, Inc. Announces Resignation Of Chief Financial Officer

diaDexus, Inc. (OTCQB:DDXS), a commercial stage developer of proprietary cardiovascular diagnostic products, today announced that Jean Viret, Ph.

DiaDexus, Inc. Secures $15 Million Debt Financing

DiaDexus, Inc. Secures $15 Million Debt Financing

diaDexus, Inc. (OTCQB:DDXS), a commercial stage developer of proprietary cardiovascular diagnostic products, today announced it has entered into a $15 million senior secured term loan with Oxford Finance.

DiaDexus, Inc. Reports Second Quarter 2014 Financial Results

DiaDexus, Inc. Reports Second Quarter 2014 Financial Results

diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the second quarter ended June 30, 2014.

DiaDexus, Inc. To Host Conference Call And Webcast July 28, 2014 To Discuss Second Quarter 2014 Financial Results

DiaDexus, Inc. To Host Conference Call And Webcast July 28, 2014 To Discuss Second Quarter 2014 Financial Results

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it will host a conference call and webcast on Monday, July 28, 2014 at 4:30 PM...

DiaDexus Announces Leadership Changes To Drive And Support Future Growth Potential

DiaDexus Announces Leadership Changes To Drive And Support Future Growth Potential

diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced leadership changes designed to expedite execution of the company’s ...

DiaDexus To Present At The Jefferies 2014 Global Healthcare Conference

DiaDexus To Present At The Jefferies 2014 Global Healthcare Conference

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that Brian E.

DiaDexus, Inc. Reports First Quarter 2014 Financial Results

DiaDexus, Inc. Reports First Quarter 2014 Financial Results

diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the first quarter ended March 31, 2014.

DiaDexus Announces Completion Of Validation Cohort For The PLAC® Test For Lp-PLA2 Activity

DiaDexus Announces Completion Of Validation Cohort For The PLAC® Test For Lp-PLA2 Activity

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced completion of the validation study that it will use to support submission of an...

DiaDexus, Inc. To Host Conference Call And Webcast May 7, 2014 To Discuss First Quarter 2014 Financial Results

DiaDexus, Inc. To Host Conference Call And Webcast May 7, 2014 To Discuss First Quarter 2014 Financial Results

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it will host a conference call and webcast on Wednesday, May 7, 2014 at 4:30 PM...

DiaDexus, Inc. Reports Fourth Quarter And Full Year 2013 Financial Results

DiaDexus, Inc. Reports Fourth Quarter And Full Year 2013 Financial Results

diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2013.

DiaDexus, Inc. Announces Exclusive U.S. Licensing Deal With Thermo Fisher Scientific To Advance Risk Prediction In Heart Failure

DiaDexus, Inc. Announces Exclusive U.S. Licensing Deal With Thermo Fisher Scientific To Advance Risk Prediction In Heart Failure

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced an exclusive licensing and supply agreement with Thermo Fisher Scientific Inc.

DiaDexus, Inc. To Host Conference Call And Webcast March 5, 2014 To Discuss Fourth Quarter And Full Year 2013 Financial Results

DiaDexus, Inc. To Host Conference Call And Webcast March 5, 2014 To Discuss Fourth Quarter And Full Year 2013 Financial Results

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it will host a conference call and webcast on Wednesday, March 5, 2014 at 4:30...

DiaDexus To Present At The Oppenheimer Healthcare Conference

DiaDexus To Present At The Oppenheimer Healthcare Conference

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that Brian E.

DiaDexus, Inc. Provides Update Related To Topline Lp-PLA2 Inhibitor Data Reported By GlaxoSmithKline

DiaDexus, Inc. Provides Update Related To Topline Lp-PLA2 Inhibitor Data Reported By GlaxoSmithKline

diaDexus, Inc. (OTCQB:DDXS), today provided an update to their PLAC® Test business related to the topline Phase 3 STABILITY trial results announced by GlaxoSmithKline (GSK).

DiaDexus, Inc. Reports Third Quarter 2013 Financial Results

DiaDexus, Inc. Reports Third Quarter 2013 Financial Results

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the third quarter ended September 30, 2013.

DiaDexus Highlights Outcome Study Showing A Reduction Of Lp-PLA2 Activity Was A Highly Significant Predictor Of Reduction In Subsequent Coronary Events

DiaDexus Highlights Outcome Study Showing A Reduction Of Lp-PLA2 Activity Was A Highly Significant Predictor Of Reduction In Subsequent Coronary Events

diaDexus, Inc. (OTCQB:DDXS) highlighted today the published observation that a reduction in Lp-PLA 2 (lipoprotein-associated phospholipase A 2) levels while on a statin treatment can reduce coronary heart disease (CHD)...

DiaDexus, Inc. Expands Loan Facility With Comerica To $10 Million

DiaDexus, Inc. Expands Loan Facility With Comerica To $10 Million

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it has amended its agreement with Comerica Bank to expand its existing loan ...

DiaDexus, Inc. To Host Conference Call And Webcast October 29, 2013 To Discuss Third Quarter 2013 Financial Results

DiaDexus, Inc. To Host Conference Call And Webcast October 29, 2013 To Discuss Third Quarter 2013 Financial Results

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it will host a conference call and webcast on Tuesday, October 29, 2013 at 4:30...

DiaDexus, Inc. Advances Clinical Validation Program For PLAC® Test For Lp-PLA2 Activity

DiaDexus, Inc. Advances Clinical Validation Program For PLAC® Test For Lp-PLA2 Activity

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it is advancing its clinical program to support the submission of the ...

DiaDexus To Present At The BIO Investor Forum

DiaDexus To Present At The BIO Investor Forum

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that Brian E.

DiaDexus, Inc. Appoints Ralf Schoenbrunner To Senior Vice President, Research And Early Development

DiaDexus, Inc. Appoints Ralf Schoenbrunner To Senior Vice President, Research And Early Development

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that E.

DiaDexus, Inc. Appoints Dr. Oye Olukotun To Board Of Directors

DiaDexus, Inc. Appoints Dr. Oye Olukotun To Board Of Directors

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular products, today announced that its Board of Directors has appointed Adeoye (Oye) Y.